CC
C4 Therapeutics, Inc.
CCCC · NASDAQ
$3.76 +1.08% (+$0.04)
1M +3.30%
Market Cap $413.5M
P/E Ratio -
Div. Yield -
ROE 45.45%
Piotroski F-Score Weak
3/9Valuation
48 /100
Fair P/S 11.80x
P/B 1.67x
P/E N/A
Growth
36 /100
Stable Rev. growth 4.95%
Book val. growth 3.91%
EPS growth N/A
Profitability
20 /100
Weak Gross margin 94.86%
Net margin 289.44%
Op. margin 318.97%
Quality
1 /100
Poor ROIC 35.21%
ROE 45.45%
ROA 28.22%
Debt
100 /100
Low Debt/Equity 0.23x
Current ratio 5.45x
Int. coverage N/A
Stability
25 /100
Unstable Beta 2.95x
Rev. volatility 53.38%
EPS volatility 22.62%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CCCC
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Andrew J. Hirsch
Employees
104
Headquarters
Watertown
Upcoming events
05 NOV
Earnings
Upcoming earnings report